The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer

BJU International

Volumn 108, Issue 8, 2011, Pages 1262-1268

  Schiavina, Riccardo ^a   Manferrari, Fabio ^a   Garofalo, Marco ^a   Bertaccini, Alessandro ^a   Vagnoni, Valerio ^a   Guidi, Mascia ^a   Borghesi, Marco ^a   Baccos, Alessandro ^a   Morselli Labate, Antonio Maria ^b   Concetti, Sergio ^a   Martorana, Giuseppe ^a  

^a TAKAMATSU RED CROSS HOSPITAL   (Japan)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

biochemical relapse; high risk prostate cancer; lymph node metastasis; pelvic lymph node dissection; prostate cancer; radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RECURRENCE RISK; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME;

AGED; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PELVIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80053386416     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.10016.x     Document Type: Article

References (29)

1. Briganti A, Blute ML, Eastham JH, et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009; 54: 1251-65
2. Schiavina R, Scattoni V, Castellucci P, et al,. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008; 54: 392-401
3. Poulsen MH, Bouchelouche K, Gerke O, et al,. [(18)F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 2010; 106: 639-43
4. Heidenreich A, Varga Z, Von Knobloch R,. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002; 167: 1681-6 (Pubitemid 34240702)
5. Eden CG, Arora A, Rouse P,. Extended vs standard pelvic lymphadenectomy during laparoscopic radical prostatectomy for intermediate- and high-risk prostate cancer. BJU Int 2010; 106: 537-42
6. Burkhard FC, Studer UE,. The role of lymphadenectomy in high risk prostate cancer. World J Urol 2008; 26: 231
7. Masterson TA, Bianco FJ Jr, Vickers AJ, et al,. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006; 175: 1320-4
8. Joslyn SA, Konety BR,. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006; 68: 121-5 (Pubitemid 44037727)
9. Murphy AM, Berkman DS, Desai M, Benson MC, McKiernan JM, Badani KK,. The number of negative pelvic lymph nodes removed does not affect the risk of biochemical failure after radical prostatectomy. BJU Int 2009; 105: 176
10. DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML,. The extent of lymphadenectomy for pTXN0 prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 2005; 173: 1121-5 (Pubitemid 40380516)
11. Cagiannos I, Karakiewicz P, Eastham JA, et al,. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003; 170: 1798-803 (Pubitemid 37254931)
12. Briganti A, Chun FK, Salonia A, et al,. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 2006; 49: 1019-26
13. Briganti A, Chun FK, Salonia A, et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 2006; 98: 788
14. Greene FL, Page DL, Fleming ID, et al,. AJCC Cancer Staging Manual, 6th edn. New York: Springer, 2002
15. Burkhard FC, Studer UE,. Regional lymph node staging in prostate cancer: prognostic and therapeutic implications. Surg Oncol 2009; 18: 213
16. TM: Prostate Cancer. Version 2.2007, 04/09/07 © 2007 National Comprehensive Cancer Network
17. Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC,. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004; 172: 1840-4 (Pubitemid 39363069)
18. Bader P, Burkhard FC, Markwalder R, Studer UE,. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003; 169: 849-54 (Pubitemid 36188105)
19. Kroepfl D, Loewen H, Roggenbuck U, Musch M, Klevecka V,. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy. BJU Int 2006; 97: 985
20. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE,. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008; 54: 344-52
21. Briganti A, Karnes JR, Da Pozzo LF, et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009; 55: 261-70
22. Daneshmand S, Quek ML, Stein JP, et al,. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004; 172: 2252-5 (Pubitemid 39507502)
23. Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA,. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Urology 2004; 63: 528-31
24. Fujisawa M, Miyake H,. Significance of micrometastases in prostate cancer. Surg Oncol 2008; 17: 247-52
25. Pagliarulo V, Hawes D, Brands FH, et al,. Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 2006; 24: 2735-42 (Pubitemid 46630570)
26. Miyake H, Kurahashi T, Hara I, Takenaka A, Fujisawa M,. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy. BJU Int 2007; 99: 315-20 (Pubitemid 46103109)
27. Ferrari AC, Stone NN, Kurek R, et al,. Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol 2006; 24: 3081-8 (Pubitemid 46638944)
28. Tarekawa T, Miyake H, Kurahashi T, Furukawa J, Takenaka A, Fujisawa M,. Improved sensitivity for detecting micrometastases in pelvic lymph nodes by real-time reverse transcriptase polymerase chain reaction (RT-PCR) compared with conventional RT-PCR in patients with clinically localized prostate cancer undergoing radical prostatectomy. BJU Int 2009; 103: 1074-8
29. Boormans JL, Wildhagen MF, Bangma CH, Verhagen PC, van Leenders GJ,. Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer. BJU Int 2008; 102: 1589